$CPE - $CRWD - $IMMU - $IOVA - On our trading list. All with news today or analyst comments & our opinions. Callon Petroleum initiated with a buy rating. Crowdstrike price target raised. IMMU CEO change and analyst reiterates Buy rating and price target. Iovance issues melanoma drug data and then does a new stock offering. Callon Petroleum initiated with a Buy at MKM Partners MKM Partners analyst John Gerdes initiated coverage of Callon Petroleum with a Buy rating and $2.00 price target. The analyst says his Q2 production target of 106.4MBOE/D is in line with guidance of over 105MBOE/D, with gross oil production forecast for 2020 at 103.6MBOE/D integrating the production curtailments in April and May. Gerdes estimates however that with oil prices assumed to recover to $45 per barrel in 2021 from $33 in 2020, Callon should generate about $70M in free cash flow next year vs. expected negative $30M this year. RBC Capital analyst Matthew Hedberg raised the firm's price target on Crowdstrike to $90 from $73 and keeps an Outperform rating on the shares ahead of its Q1 results. The analyst expects the company to deliver a strong quarter on "robust" customer adds and continued application expansion, noting that Crowdstrike remains well positioned to consolidate security spending beyond legacy AV solutions. Hedberg adds that the company should be a near- and long-term beneficiary of additional work-from-home trends. Immunomedics CEO change to not impact Trodelvy launch, says H.C. Wainwright H.C. Wainwright analyst Raghuram Selvaraju does not believe the departure of Immunomedics CEO Harout Semerjian should impact Trodelvy's potential for commercial success. The company's virtual interactions with physicians, coupled with the superior efficacy profile of Trodelvy relative to chemotherapy, should drive "healthy" market penetration near-term, Selvaraju tells investors in a research note. The analyst reiterates a Buy rating on Immunomedics with a $54 price target. Our Take: We agree the CEO change does not change any of the story. IMMU is a good biotech holding with good potential. Iovance melanoma data 'fully supportive of approval,' says Piper Sandler Iovance Biotherapeutics' interim results from lifileucel's pivotal melanoma cohort 4 last night had an overall response rate of 32.4%, inclusive of two unconfirmed responses, which is consistent with prior data for lifileucel in melanoma, namely cohort 2, Piper Sandler analyst Joseph Catanzaro tells investors in a research note. The analyst believes the data package are "fully supportive of approval" in post-PD-1 melanoma. Lifileucel's clinical profile in melanoma continues to mature "very favorably" and it remains well-positioned for a potential commercial launch in 2021, says Catanzaro, who keeps an Overweight rating on Iovance with a $40 price target. Our Take: Good news with the drug data, BUT... at the same time the company is offering more stock. So current shareholders will be diluted a bit. AND... for those thinking IOVA might be bought out, this offering of stock lessens those hopes. $IMMU, Immunomedics, Inc. / H1 Disclosure: I may trade in the ticker symbols mentioned, both long or short. My articles represent my personal opinion and analysis and should not be taken as investment advice. Readers should do their own research before making decisions to buy or sell securities. Trading and investing include risks, including loss of principal. If you liked this article, please click the LIKE (thumbs up) button. Feel free to leave any comments, question, or opinions. (Sign-up if you haven't already done so). Follow us/bookmark us and check back occasionally for additional articles or comments on our page... Wild Tiger Trading - start/main page. .Are you interested in trading stocks to supplement your income or make a living? Maybe become a professional trader? Many traders have the skills and nerves to trade, but not the upfront capital. Well now that problem is solved!Try2BeFunded has expanded its trading program! If you're a novice or experienced trader, you can earn access to a trading account with up to $100,000! To learn more about how to qualify, click HERE and give it a shot! You have nothing to lose it is free to try..